meRfi®-GM
The Digital Textbook on Gut Microbiota and Beyond
Pancreatic ductal adenocarcinoma (PDAC) / Pancreatic cancer
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer with one of the highest mortality rates, a statistic that has remained virtually unchanged for the past forty years.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult-to-treat cancers, with a 5-year survival rate of only 8%, one of the lowest of all cancers.
Pancreatic ductal adenocarcinoma (PDAC), is an aggressive cancer surrounded by a highly immuno-suppressive tumor microenvironment (TME) which limits efficacy of most available therapies
…
References (Sources)
- Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
- Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion
- Estimated projection of US cancer incidence and death to 2040
- From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
- Locally advanced pancreatic cancer: An emerging entity
- Pancreatic Cancer: Challenge and Inspiration
- The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer